• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    GH Research (GHRS) Looks Pricey Following Wider Losses In Its Latest Earnings Report

    Simply Wall St·08/11/2026 13:25:58
    Listen to the news

    GH Research (NasdaqGM:GHRS) drew investor attention after reporting second quarter 2026 results, with a net loss of US$15.15 million and a basic loss per share from continuing operations of US$0.23.

    See our latest analysis for GH Research.

    Despite the wider loss just reported, GH Research’s share price has climbed strongly over 2026, with a year to date share price return of 123.04% and a 1 year total shareholder return of 150.25%, signalling strong positive momentum in investor sentiment.

    If GH Research’s recent move has you thinking about where else growth stories might emerge in healthcare and AI, it could be worth scanning 43 healthcare AI stocks.

    The jump in GH Research’s share price sits against widening losses, which raises a simple question. Is the recent run more about confidence in the pipeline, or is it a short term swing in sentiment before valuation catches up?

    Preferred Price to Book Ratio of 5.6x: Is it justified?

    With GH Research trading at a P/B of 5.6x, compared with 2.6x for the wider US pharmaceuticals sector and 5.2x for its peer group, the stock is priced at a clear premium to book value.

    P/B compares a company’s market value with its net assets on the balance sheet. For a clinical stage biopharmaceutical company like GH Research that currently reports no revenue and a net loss of $62.27m, investors often focus less on current earnings and more on balance sheet strength, pipeline potential and funding capacity.

    The premium P/B suggests investors are placing a higher value on GH Research’s assets and development pipeline than the sector average, even though the company is unprofitable, is forecast to remain unprofitable over the next 3 years, and is expected to have no revenue next year. With 100% of liabilities coming from higher risk funding sources and a negative return on equity, the current multiple implies strong confidence in future outcomes and a higher tolerance for execution and financing risk.

    Compared with the US pharmaceuticals industry average of 2.6x, GH Research’s 5.6x P/B is more than double the sector level, and it also sits above the 5.2x peer average. That places the stock in the more expensive group on a book value basis, which means any change in sentiment around trial progress, funding conditions or the pace of development could matter more for shareholders when this multiple eventually normalizes.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book ratio of 5.6x (OVERVALUED)

    However, GH Research still faces key risks if trial outcomes disappoint or funding conditions tighten, which could challenge the current premium and sentiment-driven share price.

    Find out about the key risks to this GH Research narrative.

    Next Steps

    With sentiment around GH Research clearly mixed, this is a good moment to check the underlying data yourself and move quickly if needed. Start by weighing the 2 important warning signs.

    Looking for more investment ideas beyond GH Research?

    If GH Research has sharpened your interest, do not stop here. Use proven filters to uncover other stocks that fit the kind of portfolio you want to build.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.